Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
OpenAI Restricts Astra AI Over Cyberattack Risks 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
PARSIPPANY, N.J., March 06, 2018 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the company is scheduled to participate in an analyst-led fireside chat at the 2018 Barclays Global Healthcare Conference at 11:15 AM ET on Tuesday, March 13, 2018 in Miami.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company dedicated to advancing and improving postsurgical outcomes for acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.
Company Contact:
Pacira Pharmaceuticals, Inc.
Christian Pedetti
(973) 254-4387
[email protected]
